Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qinggan Jiangya Capsule for primary hypertension
ChiCTR1800015022Phase 4Recruiting
- Sponsor
- Beijing University of Chinese Medicine
- Start
- Jul 2017
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of qinggan jiangya in essential hypertension (2 arms), sponsored by Beijing University of Chinese Medicine. Primary endpoints: Average change in sitting systolic blood pressure from baseline at week 2, Average change in sitting diastolic blood pressure from baseline at week 2 and 2 more. Started Jul 2017; status: recruiting.
02
Drugs
qinggan jiangya
03
Conditions
essential hypertension
Beyond the preview
Go deeper on ChiCTR1800015022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015022.